Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies

被引：2
|
作者：
Niscola, Pasquale [1 ]
Gianfelici, Valentina [1 ]
Catalano, Gianfranco [2 ]
Giovannini, Marco [1 ]
Mazzone, Carla [1 ]
Noguera, Nelida Ines [2 ,3 ]
de Fabritiis, Paolo [1 ,2 ]
机构：
[1] S Eugenio Hosp ASL Roma 2, Hematol Unit, I-00144 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Biomed & Prevent, I-00133 Rome, Italy
[3] IRCCS, St Lucia Fdn, Neurooncoemtol Units, I-00143 Rome, Italy
来源：
CURRENT ONCOLOGY | 2024年 / 31卷 / 11期
关键词：
genomic profiling; targeted therapies; hypomethylating agents; venetoclax-based combinations; intensive chemotherapy; transplantation clinical trials; supportive care; quality of life; HEALTH-ORGANIZATION CLASSIFICATION; MEASURABLE RESIDUAL DISEASE; VENETOCLAX-BASED THERAPY; GILTERITINIB; AZACITIDINE; METABOLISM; CHEMOTHERAPY; NEOPLASMS; EVOLUTION; CRITERIA;
D O I：
10.3390/curroncol31110490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Acute myeloid leukemia (AML) is a heterogeneous blood-related neoplasm that predominantly afflicts older adults with a poor prognosis due to their physical condition and the presence of medical accompanying comorbidities, adverse biological disease features, and suitability for induction intensive chemotherapy and allogenic stem cells transplantation. Recent research into the molecular and biological factors contributing to disease development and progression has led to significant advancements in treatment approaches for older patients with AML. This review article discusses the latest biological and therapeutic developments that are transforming the management of AML in older adults.
引用
收藏
页码：6632 / 6658
页数：27
相关论文
共 50 条
  • [31] Management of primary refractory acute myeloid leukemia in the era of targeted therapies
    McMahon, Christine M.
    Perl, Alexander E.
    LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 583 - 597
  • [32] Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia
    Kropp, Erin M.
    Li, Qing
    EXPERIMENTAL HEMATOLOGY, 2022, 111 : 13 - 24
  • [33] Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape
    Eman T. Al-Antary
    Avanti Gupte
    Yaddanapudi Ravindranath
    Indian Journal of Pediatrics, 2024, 91 : 176 - 183
  • [34] Treatment of acute myeloid leukemia in older patients
    Roboz, Gail J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (03) : 285 - 295
  • [35] The challenge of acute myeloid leukemia in older patients
    Sekeres, MA
    Stone, RM
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (01) : 24 - 30
  • [36] The new perspectives of targeted therapy in acute myeloid leukemia
    Walasek, Angela
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (02): : 271 - 276
  • [37] THE ROLE OF MICRORNAS IN RESPONSE TO NEW TARGETED THERAPIES IN CHRONIC MYELOID LEUKEMIA
    Veiga, S.
    Pires, A.
    Alves, R.
    Fernandes, S.
    Matafome, P.
    Seica, R.
    Goncalves, A. C.
    Sarmento Ribeiro, A. B.
    HAEMATOLOGICA, 2015, 100 : 428 - 429
  • [38] Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia
    Campos, Elisabete do Vale
    Pinto, Ricardo
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2019, 41 (02) : 169 - 177
  • [39] Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia
    Patel, Shyam A.
    Litzow, Mark R.
    Cerny, Jan
    BLOOD REVIEWS, 2021, 50
  • [40] Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia
    Jabbour, Elias
    Cortes, Jorge
    Ravandi, Farhad
    O'Brien, Susan
    Kantarjian, Hagop
    SEMINARS IN HEMATOLOGY, 2013, 50 (04) : 271 - 283
12345